Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 8/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5025734 | 1.00 | LSS (0.53) | LSSLMNAGAAL3MBTL1MAPT | |
| SCHEMBL5024179 | 0.93 | LSS (0.55) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL5024177 | 0.93 | LSS (0.55) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL5164450 | 0.91 | LSS (0.51) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL5164456 | 0.91 | LSS (0.51) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL6018794 | 0.84 | LSS (0.55) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL6018796 | 0.84 | LSS (0.55) | LSSLMNAL3MBTL1MAPTACHE | |
| SCHEMBL5025718 | 0.83 | LSS (0.68) | LSSLMNAL3MBTL1ACHECYP1A2 | |
| SCHEMBL5025719 | 0.83 | LSS (0.68) | LSSLMNAL3MBTL1ACHECYP1A2 | |
| SCHEMBL5024153 | 0.83 | LSS (0.54) | LSSLMNAL3MBTL1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442791-B2 | Aminoalkylamide substituted cyclohexyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1667962-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028427-A1 | AMINOALKYLAMIDE SUBSTITUTED CYCLOHEXYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065210-A1 | Aminoalkylamide substituted cyclohexyl derivatives | LSS, CYP51A1, CYP46A1 | LSS 1/4885LMNA 1652/4885GAA 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.